PMID- 31295004
OWN - NLM
STAT- MEDLINE
DCOM- 20200818
LR  - 20221207
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Linking)
VI  - 29
IP  - 9
DP  - 2019 Nov
TI  - Selective Serotonin Reuptake Inhibitor Monotherapy for Anxiety Disorders in 
      Children and Adolescents with Autism Spectrum Disorder: A Chart Review.
PG  - 705-711
LID - 10.1089/cap.2019.0001 [doi]
AB  - Objective: Anxiety disorders are one of the most commonly co-occurring 
      psychiatric diagnoses in youth with autism spectrum disorder (ASD), with a 
      frequency ranging from 22% to 84%. Methods: We conducted a chart review of 29 
      children and adolescents with ASD who had been treated with selective serotonin 
      reuptake inhibitor (SSRI) monotherapy for an anxiety disorder for at least 2 
      months. Subsequent chart reviews were conducted for the first follow-up visit 
      within 2-6 months (M = 4.2 months) and the visit closest to 9 months 
      posttreatment (ranging from 7 to 12 months; M = 10.5 months). The presence of 
      adverse events (AEs) was examined, and a consensus Clinical Global Impressions 
      Improvement (CGI-I) score was determined. Results: Fifty-five percent of patients 
      were given a CGI-I of "improved" or "very much improved" at the 9-month 
      follow-up. Four patients discontinued treatment owing to AEs. Other reported AEs 
      not leading to discontinuation included vivid dreaming, increased emotional 
      lability, and irritability. Responders included a number of patients who had 
      failed previous SSRI trials. Conclusions: This study suggests that SSRI treatment 
      should be considered for individuals with ASD and anxiety disorders, even if 
      prior SSRI trials have been unsuccessful.
FAU - Thorkelson, Gregory
AU  - Thorkelson G
AD  - Department of Psychiatry, Western Psychiatric Hospital, University of Pittsburgh 
      School of Medicine, Pittsburgh, Pennsylvania.
FAU - Laughlin, Sarah F
AU  - Laughlin SF
AD  - Department of Physical Medicine and Rehabilitation, UPMC Children's Hospital of 
      Pittsburgh, Pittsburgh, Pennsylvania.
FAU - Turner, Kylan S
AU  - Turner KS
AD  - Department of Behavior Analysis, Simmons University, Boston, Massachusetts.
FAU - Ober, Nicole
AU  - Ober N
AD  - Department of Psychiatry, Western Psychiatric Hospital, University of Pittsburgh 
      School of Medicine, Pittsburgh, Pennsylvania.
FAU - Handen, Benjamin L
AU  - Handen BL
AD  - Department of Psychiatry, Western Psychiatric Hospital, University of Pittsburgh 
      School of Medicine, Pittsburgh, Pennsylvania.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190711
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - Adolescent
MH  - Anxiety Disorders/*drug therapy
MH  - *Autism Spectrum Disorder
MH  - Citalopram/*therapeutic use
MH  - *Comorbidity
MH  - Female
MH  - Fluoxetine/*therapeutic use
MH  - Humans
MH  - Male
MH  - Retrospective Studies
MH  - Selective Serotonin Reuptake Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - SSRI
OT  - anxiety disorders
OT  - autism spectrum disorder
EDAT- 2019/07/12 06:00
MHDA- 2020/08/19 06:00
CRDT- 2019/07/12 06:00
PHST- 2019/07/12 06:00 [pubmed]
PHST- 2020/08/19 06:00 [medline]
PHST- 2019/07/12 06:00 [entrez]
AID - 10.1089/cap.2019.0001 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2019 Nov;29(9):705-711. doi: 
      10.1089/cap.2019.0001. Epub 2019 Jul 11.